License CRG Technologies

Explore our Technology Portfolio

If you are exploring licensing opportunities at the CRG, the TBDO can guide you to a wide range of suitable researchers and their technologies.

Novel Targets and Compounds to Treat Bladder Cancer

Alternative splicing modulating antisense oligonucleotides (ASOs) targeting novel identified alternative splicing changes associated with RBM10 mutations in bladder cancer.

 

We are developing lead ASOs to treat bladder, and eventually other, cancers.

 

Technology:

Bladder cancer is the 9th most common malignant disease worldwide and 13 most frequent cause of cancer death. 80 % of those cancers are non-muscle invasive bladder cancers (NMIBC) while 20 % are muscle invasive (MIBC). While the survival rate after diagnosis in the earlier NMIBC stages is good, it is low for MIBC cancers. Even for NMIBC, patient lives are severely affected because cancer relapses in 60–70 % of the cases and regular check-ups are necessary. These check-ups are not straightforward and have not only a high impact on the patients personal and sex life but are also very costly. Bladder cancer treatment has the highest cost per patient from diagnosis to death.

The alternative splicing factor RBM10 has been found to be frequently mutated in both, NMIBC and MIBC. Through an extensive sequencing and genetic analysis, the CRG team explored, identified and validated the consequences of RBM10 mutations on specific alternative splicing events. The team developed and validated ASOs that correct those RBM10-induced changes of those specific alternative splicing events that can be used to treat bladder, and eventually other, cancers.

Patent Information:
IP Status

Available for licensing / partnering / co-development, etc.

 

For Information, Contact:
Peter Stienen peter.stienen@crg.eu
CRG Inventors:
Juan Valcarcel
Ángel Guerra
Tobias Hoffmann
Keywords:

 

 

Categories

Featured Technologies

Most Popular Keywords

Latest Technologies Published

Search our database for an up-to-date listing of CRG intellectual property available for licensing